Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
IXQUF (IXQUF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: IXQUF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.09% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 10.35 - 12.89 | Updated Date 05/3/2025 |
52 Weeks Range 10.35 - 12.89 | Updated Date 05/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84650568 | Price to Sales(TTM) - |
Enterprise Value 84650568 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1610376 |
Shares Outstanding - | Shares Floating 1610376 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
IXQUF
Company Overview
History and Background
IXQUF represents shares of iX Biopharma Ltd, a Singapore-based pharmaceutical company. Founded in 2007, iX Biopharma focuses on the development and commercialization of novel therapies for pain management, supportive care, and other areas. It has evolved from early stage research to commercial production and distribution of its products.
Core Business Areas
- Pharmaceuticals: Develops and commercializes pharmaceuticals for pain management and supportive care.
- Nutraceuticals: Produces and sells nutraceutical products.
- Drug Delivery: Specializes in sublingual drug delivery systems through its WaferiX technology platform.
Leadership and Structure
The company is led by a board of directors and executive management team. The organizational structure is hierarchical, with departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- WaferiX Technology: Proprietary sublingual wafer technology for rapid drug delivery. Market share data is not readily available. Competitors include companies developing other rapid dissolving tablet (RDT) technologies like Catalent and CIMA Labs (now part of Cephalon/Teva Pharmaceuticals).
- BNOX (Sublingual Ketamine): A sublingual ketamine formulation for acute pain management. Market share data is not readily available as it's subject to regulatory approvals and market entry in different regions. Competitors include companies developing IV ketamine formulations and other pain management drugs, such as opioids marketed by Purdue Pharma (bankruptcy) and non-opioid alternatives.
- Xativa: Sublingual wafer for male sexual dysfunction. Market share data is not readily available. Competitors include companies with products like sildenafil (Viagra by Pfizer, generic versions available) and tadalafil (Cialis by Eli Lilly, generic versions available).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The nutraceutical industry is growing but fragmented.
Positioning
IXQUF aims to differentiate itself through its WaferiX technology and its focus on sublingual drug delivery, which offers advantages such as faster absorption and improved bioavailability. However it is a very small player relative to global pharmaceutical companies. Its competitive advantage is in proprietary drug delivery.
Total Addressable Market (TAM)
The pain management and supportive care market is estimated to be in the billions of dollars globally. The nutraceuticals market is also substantial. IXQUF's position within the TAM depends on the successful commercialization of its products and its ability to secure regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary WaferiX drug delivery technology
- Focus on sublingual administration for improved drug delivery
- Developing novel formulations for pain management and supportive care
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on regulatory approvals for product commercialization
- Market access challenges in competitive pharmaceutical markets
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Geographic expansion into new markets
- Continued development of WaferiX technology platform
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- PFE
- MRK
- JNJ
Competitive Landscape
IXQUF faces intense competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its WaferiX technology and its focus on niche therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has likely been driven by the development and potential commercialization of its products.
Future Projections: Future growth depends on the successful commercialization of its products, regulatory approvals, and market acceptance.
Recent Initiatives: Recent initiatives include clinical trials for its drug candidates, partnerships for manufacturing and distribution, and efforts to secure regulatory approvals in key markets.
Summary
IXQUF is a small pharmaceutical company focused on sublingual drug delivery. Its proprietary WaferiX technology offers potential advantages, but it faces significant competition from larger companies. Regulatory approvals and successful commercialization are crucial for its future growth. The company needs to secure strategic partnerships to expand its market reach. Financial data transparency needs improvement to attract broader investor interest.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Company Press Releases
- Publicly Available Industry Reports
- Analyst Reports (if available)
Disclaimers:
The data provided is based on publicly available information and is subject to change. This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise. Investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IXQUF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-07 | CEO, CFO, COO & Director Mr. Noah Aptekar | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.ixacq.com |
Full time employees - | Website https://www.ixacq.com | ||
IX Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on companies in technology, media and telecommunications, and information and communication technology industries, as well as companies operating in telecommunications infrastructure, internet and technology, and digital services sectors in Europe and other markets. The company was incorporated in 2021 and is based in London, United Kingdom. IX Acquisition Corp. is a subsidiary of IX Acquisition Sponsor LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.